Thymosin alpha‑1 (Tα1) is a tiny peptide that boosts T‑cell function and has a solid safety record. Recent clinical data show it can improve overall survival after surgery for lung and liver cancers, lessen the drop in immune cells caused by chemo‑radiation, and may help turn “cold” tumors into “hot” ones that respond better to checkpoint‑inhibitor drugs. Pre‑clinical work also suggests it can reduce side‑effects like colitis from those immunotherapies.
Iino. S S; Toyota. J J; Kumada. H H; Kiyosawa. K K; Kakumu. S S; Sata. M M; Suzuki. H H; Martins. E...
Thymosin‑alpha‑1 (Tα1) taken at either 0.8 mg or 1.6 mg daily for 24 weeks helped a good share of chronic hepatitis B patients lower liver enzymes, clear the virus from the blood, and lose the HBe‑antigen, with benefits still visible a year after stopping the drug. Side effects were mild and similar at both doses.
Tuthill. Cynthia C; Rios. Israel I; De Rosa. Alfonso A; Camerini. Roberto R
Thymosin‑alpha‑1 is a short peptide that can boost how well your body responds to vaccines. In both animal work and human studies it helped older or otherwise immune‑compromised people make more antibodies and stronger T‑cell defenses, even cutting down the number of vaccine shots needed in some cases. Giving the peptide twice around the time of a flu shot led to a faster and bigger immune response.
A study found that adding the peptide thymosin‑alpha‑1 to sperm samples boosted the ability of sperm from infertile men to fertilize eggs, with about three‑quarters of participants showing a 31‑45% improvement.
Carraro. G G; Naso. A A; Montomoli. E E; Gasparini. R R; Camerini. R R; Panatto. D D; Tineo. M C MC;...
In a small pilot study, adding the peptide Thymosin‑alpha‑1 to a pandemic H1N1 flu shot made the vaccine work better in people on dialysis, who normally have weak immune responses. Both low (3.2 mg) and higher (6.4 mg) doses improved antibody levels without extra side effects, suggesting the peptide can safely boost vaccine effectiveness.
Scientists built a bacteria strain that can make the peptide thymosin‑alpha‑1, then cut it out to get about 0.2 g of pure, active peptide per litre of culture. The process is fairly efficient and the product works like the natural version, meaning hobby labs could potentially produce their own supply if they have the right equipment.
Bianco-Batlles. D D; Naylor. C W CW; Moshier. J A JA; Dosescu. J J; Naylor. P H PH
The study shows that exposing thymosin‑alpha‑1 to the acid trifluoroacetic acid (TFA) wipes out its immune‑boosting effects, even though standard lab tests like HPLC can’t tell the difference. Heat doesn’t harm the peptide, so the loss of activity is specific to TFA. This means how you handle and store the peptide matters a lot for it to work.
A Chinese clinical trial tested a step‑by‑step treatment for chronic hepatitis B that starts with thymosin‑alpha‑1, adds interferon, then later adds lamivudine. This “sequential” plan gave much higher rates of virus‑clearance markers and liver‑enzyme normalization than using lamivudine alone, and performed about as well as giving thymosin‑alpha‑1 and interferon together from the start.
Minutolo. Antonella A; Petrone. Vita V; Fanelli. Marialaura M; Maracchioni. Christian C; Giudice. Ma...
The study shows that thymosin‑alpha‑1 can help fix the messed‑up immune system seen in people with long COVID, especially those who were very sick during the infection, by boosting low‑count T‑cells and improving some lingering physical and mental symptoms.
Wu. Ming M; Ji. Jing-Jing JJ; Zhong. Li L; Shao. Zi-Yun ZY; Xie. Qi-Feng QF; Liu. Zhe-Ying ZY; Wang....
A study in China looked at giving the peptide thymosin‑alpha‑1 to very sick COVID‑19 patients. It found that people who got the drug were less likely to die within 28 days, especially those who were older and had worse lab numbers. The benefit was seen mainly in the most critical cases, and the drug also seemed to improve lung oxygen levels.
This paper reviews how thymosin‑alpha‑1, a peptide that boosts the immune system, is being used alongside standard lung‑cancer treatments. It shows that adding thymosin can improve patient outcomes in some studies, but the exact doses and schedules aren’t settled yet. The review also points to future research needed before it becomes a routine part of cancer care.
Scientists made a new version of the immune‑boosting peptide thymosin‑alpha‑1 that sticks around in the blood much longer by attaching a big, floppy PAS chain and adding an acetyl group. In rats the modified peptide lasted over eight times longer than the regular one, meaning fewer injections could be needed. The method also makes the peptide easier to produce and more stable, but it’s still only tested in animals, not humans.
Ricci. Daniela D; Etna. Marilena Paola MP; Severa. Martina M; Fiore. Stefano S; Rizzo. Fabiana F; Ia...
This study shows that the peptide thymosin‑alpha‑1 can calm down the early immune over‑reaction seen in COVID‑19 by lowering harmful inflammatory signals and boosting a calming signal, at least in lab‑grown blood cells. It doesn’t give dosing tips or human trial results, but it supports the idea that Tα1 might help manage the “cytokine storm” during viral infections.
A big review of 39 trials found that adding the peptide thymosin‑alpha‑1 to standard care helped people with sudden flare‑ups of COPD breathe better, get more oxygen, have lower carbon‑dioxide levels, stay in hospital shorter, and showed stronger immune cells.
A big study in China looked at people with COVID‑19 who got the peptide thymosin‑alpha‑1 and found they did worse than those who didn’t get it. They were more likely to stay sick, die, need a ventilator, develop lung injury, kidney injury, and spend longer in the ICU. Starting the peptide later or using it in very sick patients made the risk even higher.
A study of 338 COVID‑19 patients found that those given thymosin‑alpha‑1 (Thymalfasin) got better faster – they stayed in the hospital shorter, were less likely to become severely ill, cleared the virus quicker, and felt less fever and fatigue.
Ke. Lu L; Mao. Wenjian W; Shao. Fang F; Zhou. Jing J; Xu. Minyi M; Chen. Tao T; Liu. Yuxiu Y; Tong....
The study found that the immune‑boosting peptide thymosin‑alpha‑1 can lower the chance of infected pancreatic tissue death in severe pancreatitis, but only in patients who already have a decent number of lymphocytes (a type of white blood cell). People with low lymphocyte counts didn’t see the benefit. This suggests the drug works best when the immune system isn’t already weakened.
Gao. Chun C; Zhu. Li L; Tong. Yi Xin YX; Zhang. Sheng S
After stomach cancer surgery, patients lose a lot of immune cells like T, B, and NK cells. Giving the peptide thymosin‑alpha‑1 helped keep these cells from dropping as much, especially T and B cells. This suggests the peptide can protect the immune system during big physical stress, though the study was in cancer patients, not healthy people.
Adding the immune‑boosting peptide thymosin‑alpha‑1 (thymalfasin) to the standard antiviral drug entecavir helped patients with chronic hepatitis B show lower liver enzymes, better immune cell counts, and reduced markers of liver scarring compared to entecavir alone.
Cheng. Yuya Y; Wu. Peize P; Kan. Ying Y; Li. Ming M; Li. Hongmei H
The study mapped out many tiny chemical variations (impurities) in the peptide thymosin‑alpha‑1, showing that most of them come from the last building block (asparagine) which isn’t needed for its immune‑boosting effect. This means commercial products may contain unwanted side‑products, and a cleaner version could be made by removing or altering that last piece.